Description: Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Home Page: www.evotec.com
Essener Bogen 7
Hamburg,
22419
Germany
Phone:
49 40 560 81 0
Officers
| Name | Title |
|---|---|
| Dr. Werner Lanthaler M.B.A., MBA, MPA, Ph.D. | Chairman of Management Board & CEO |
| Mr. Enno Spillner | CFO & Member of Management Board |
| Dr. Cord Dohrmann Ph.D. | Chief Scientific Officer & Member of Management Board |
| Dr. Craig Johnstone | COO & Member of Management Board |
| Dr. Matthias Evers | Chief Bus. Officer & Member of Management Board |
| Ms. Anja Bosler | Principal Accounting Officer and Sr. VP of Group Accounting |
| Mr. Volker Braun | Sr. VP and Global Head of Investor Relations & ESG |
| Dr. Christian Dargel | EVP Global Head of Legal & Compliance |
| Gabriele Hansen | Sr. VP & Head of Global Corp. Communications & Marketing |
| Ms. Monika Conradt | Global Head of HR |
Exchange: XETRA
Country: DE
Currency: Euro (€)
| Forward PE: | 90.9091 |
|---|---|
| Trailing PE: | 446 |
| Price-to-Book MRQ: | 2.3406 |
| Price-to-Sales TTM: | 3.9089 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 4715 |